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Summary
 
Protein C is an important regulatory mechanism of blood coagulation. Protein C functions as
an anticoagulant when converted to the active serine protease form on the endothelial cell sur-
face. Thrombomodulin (TM), an endothelial cell surface receptor specific for thrombin, has
been identified as an essential component for protein C activation. Although protein C can be
activated directly by the thrombin–TM complex, the conversion is known as a relatively low-
affinity reaction. Therefore, protein C activation has been believed to occur only in microcir-
culation. On the other hand, we have identified and cloned a novel endothelial cell surface re-
ceptor (EPCR) that is capable of high-affinity binding of protein C and activated protein C. In
this study, we demonstrate the constitutive, endothelial cell–specific expression of EPCR in
vivo
 
.
 
 Abundant expression was particularly detected in the aorta and large arteries. In vitro cul-
tured, arterial endothelial cells were also found to express abundant EPCR and were capable of
promoting significant levels of protein C activation. EPCR was found to greatly accelerate
protein C activation by examining functional activity in transfected cell lines expressing EPCR
and/or TM. EPCR decreased the dissociation constant and increased the maximum velocity
for protein C activation mediated by the thrombin–TM complex. By these mechanisms,
EPCR appears to enable significant levels of protein C activation in large vessels. These results
suggest that the protein C anticoagulation pathway is important for the regulation of blood co-
agulation not only in microvessels but also in large vessels.
 
P
 
rotein C pathway is an indispensable regulatory mecha-
nism of blood coagulation, since deficiencies in this
pathway lead to thrombosis (1, 2). Protein C is a 
 
g
 
-carboxy-
glutamic acid containing protein (3) and circulates as a zy-
mogen form of serine protease (4). Protein C functions as
an anticoagulant when converted to its active form by
thrombin (5), and activation of protein C was demon-
strated to be greatly enhanced on the endothelial cell sur-
face (6). Thrombomodulin (TM)
 
1
 
 has been identified as an
essential component on the endothelial cell surface (7, 8),
and direct activation of protein C by the thrombin–TM
complex has been demonstrated. However, the activation
by the complex was observed as a relatively low-affinity re-
action and the 
 
K
 
d
 
 value was calculated as 0.7–1.0 
 
m
 
M (9–
11), which is 15 times higher than that of the protein C
concentration (65 nM) in the circulation (12). Under these
conditions, protein C activation appears unlikely to occur
under normal physiological conditions. One of the pro-
posed explanations for this has been that protein C activa-
tion mediated by the thrombin–TM complex occurs only
in the microcirculation because of the greater ratio of en-
dothelial cell surface area to blood volume (13).
On the other hand, we (14) and others (15) found that
protein C and activated protein C (APC) bound to cul-
tured endothelial cells with a relatively high affinity (
 
K
 
d
 
 5 
 
30
nM). By expression cloning, we identified a novel endo-
thelial cell surface receptor that is capable of protein C–APC
binding in the presence of physiological concentrations of
calcium (14) and magnesium (16). We designated this mol-
ecule as an endothelial cell protein C–APC receptor (EPCR).
EPCR is a type 1 transmembrane glycoprotein containing
 
1
 
Abbreviations used in this paper:
 
 AEC, arterial endothelial cell; APC, acti-
vated protein C; EPCR, endothelial cell protein C-APC receptor; TM,
thrombomodulin; VEC, venous endothelial cell.
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two domains in the extracellular region that are homolo-
gous to the 
 
a
 
1 and 
 
a
 
2 domains of CD1/MHC class 1 mol-
ecules (17). The highly conserved structural features and
ligand binding function of EPCR that are found between
species suggests an important physiological function for the
receptor molecule (18). In
 
 
 
in vitro cultured human cells,
significant levels of EPCR expression has been demon-
strated only in human umbilical vein endothelial cells (14).
In this study, we demonstrate in vivo expression of EPCR
by immunohistochemical analysis. The abundant expres-
sion of EPCR was found on the endothelial cells of the
aorta where protein C activation has been considered
unlikely to occur. In addition, we found that protein C
activation mediated by the thrombin–TM complex was
promoted as a relatively high-affinity reaction in the pres-
ence of EPCR. 
 
Materials and Methods
 
 Cells.
 
Human primary venous endothelial cells (VECs) and
arterial endothelial cells (AECs) were obtained from Cell Systems
(Kirkland, WA) and maintained according to the manufacturer’s
protocol. Human kidney 293 cells (CRL 1573; American Type
Culture Collection, Rockville, MD) were maintained in DMEM
containing 10% fetal bovine serum. Stable transfected cell lines of
293 cells expressing human EPCR and/or TM were established
as follows. Cells were transfected with a human EPCR cDNA
construct in a mammalian expression vector, pEF-BOS (19),
and/or a human TM cDNA (a gift from J.F. Parkinson, Lilly Re-
search Lab., Indianapolis, IN) constructed in a mammalian ex-
pression vector pBK-EF (a gift from T. Fujimoto, Hiroshima
University, Hiroshima, Japan) by the calcium/phosphate method
as described (14). Cell lines were established by G-418 selection,
followed by subcloning. T2 cells are positive for TM. ET1 cells
and ET2 cells are positive for both EPCR and TM. Establishment
of these cell lines was done in the Oklahoma Medical Research
Foundation (Oklahoma City, OK) under the support of C.T. Esmon
(Oklahoma Medical Research Foundation). Negative control N1
cells and EPCR positive E7 cells were established as described (16).
 
 Histology. 
 
Sections (4 
 
m
 
m) of human aorta and lung were fixed
in cold acetone, paraffin embedded processed, and then stained with
JRK-1, an anti-EPCR mouse monoclonal antibody, or CTM1009,
an anti-TM mouse monoclonal antibody (a gift from C. Carson,
Oklahoma Medical Research Foundation, Oklahoma City, OK).
Antigen expression was then detected using biotinylated anti–
mouse Ig, streptavidin-conjugated horseradish peroxidase, and
3,3
 
9
 
-diaminobenzidine as previously described (20). 
 
 Flow Cytometry. 
 
Cells were harvested and stained with JRK-1
or CTM1009 as described (14). The antigen expression was de-
tected on a FACScan
 
Ò
 
 flow cytometer (Becton Dickinson,
Sunnyvale, CA) by using FITC-conjugated goat anti–mouse IgG
(Southern Biotechnology Associates, Inc., Birmingham, AL).
Living cells were gated by staining with propidium iodide. Data
analysis was performed by using the Win MDI program (J. Trot-
ter, Scripps Research Institute, La Jolla, CA). 
 
 Protein C Activation Assay. 
 
Monolayers of AECs or VECs
were formed by overnight culture in 48-well microplates coated
with gelatin. After washing with PBS containing 0.5 mM EDTA,
the cells were incubated with various concentrations of human
protein C in 100 
 
m
 
l of HBSS containing 0.1% BSA in the ab-
sence or presence of human thrombin (0.1 U final concentra-
tion). The plates were incubated at 37
 
8
 
C for 30 min. To stop the
reaction, antithrombin III, at a final concentration of 1 
 
m
 
g/ml,
and EDTA, at a 5 mM final concentration, were added and the
plates were incubated for a further 5 min. Aliquots were trans-
ferred to 96-well microplates and a chromogenic substrate, S-2366
(AB Kabi Diagnostica, Stockholm, Sweden), was added at a final
concentration of 200 
 
m
 
M. The catalytic rate of the substrate was
measured by absorbance at 405 nm by using a V
 
max
 
 kinetic micro-
plate reader (Molecular Devices Co., Sunnyvale, CA). Generated
APC was estimated by using a standard curve of purified APC.
The same experiments were also carried out by using monolayers
of transfected human 293 cells (see above) formed in microplates
coated with poly-L-lysine (Sigma Chemical Co., St. Louis, MO).
The 
 
K
 
d
 
 and V
 
max
 
 values were calculated using the Hyper program
(J.S. Easterby, University of Liverpool, Liverpool, UK). 
 
Results and Discussion
 
 In a previous study, we demonstrated that the message
expression of EPCR was demonstrable only with HU-
VECs among in vitro cultured human cells (14). The mes-
senger RNA was also detectable in normal tissues by North-
ern blot analysis (data not shown). Abundant expression
was detected in heart and placenta, and the message was
also present in lung, kidney, and pancreas, although brain
was negative for the message. To investigate the detailed
expression pattern of EPCR, we performed immunohis-
tochemical analysis of human tissues using an anti-EPCR
monoclonal antibody and anti-EPCR goat Ig (16). Consti-
tutive, endothelial cell–specific expression of EPCR was
demonstrated with these antibodies. The most abundant
expression of EPCR was detected on the endothelial cells
of the aorta (Fig. 1 
 
A
 
). Moderate expression was also de-
tected on the endothelial cells of relatively large-sized ves-
sels (data not shown). On the other hand, little or no ex-
pression could be detected in microvessels such as the lung
capillaries (Fig. 1 
 
C
 
). 
We also examined serial sections using an anti-TM mono-
clonal antibody. TM was expressed widely in both arterial
and venous vessels as described (21), and strong expression
was detected in the capillaries (data not shown). These re-
sults indicated that EPCR and TM coexpress on the endo-
thelial cells in vessels with relatively large size. Coexpres-
sion of EPCR and TM was also demonstrated by the flow
cytometer analysis using in vitro cultured endothelial cells
(Fig. 2). Strong expression of EPCR was detected on cul-
tured AECs. EPCR was also detectable in cultured VECs;
however, the expression level was several times lower than
that in the AECs. TM was expressed on both AECs and
VECs. In contrast to EPCR, strong expression of TM was
detected on VECs and a lower and heterogeneous expres-
sion was detected on AECs. 
Since the dissociation constant between protein C and
EPCR is 30 nM, which is approximately half of the blood
concentration of protein C, the majority of EPCRs ex-
posed to the blood stream should be holding protein C un-
der physiological conditions. These findings encouraged us
to reinvestigate the mechanism of protein C activation,
which has been believed to be mediated by only the 
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thrombin–TM complex. We compared activities of protein
C activation by AECs and VECs, which express different
amounts of EPCRs and TM on their surface (Fig. 2). In
both cases, protein C was converted to APC only in the
presence of thrombin. Interestingly, promotion of protein
C activation by AECs was comparable to VEC-mediated
activation (Fig. 3), despite the lower level of TM expres-
sion (Fig. 2). In addition, activation of protein C on AECs
was observed as a relatively high-affinity reaction with a 
 
K
 
d
 
value of 125 
 
6
 
 72 nM, suggesting contribution by the
high-affinity protein C receptor to the reaction. The 
 
K
 
d
 
value for the reaction by VECs was slightly lower (162 
 
6
 
54 nM) than that of AECs. This could be due to the low
level of expression of EPCR on VECs. 
To analyze in detail the activation mechanism, we estab-
lished transfected human kidney 293 cell lines that express
receptor molecules. The 293 cells are negative for EPCR
and TM. Mock-transfected N1 cells are used as a negative
control, E7 cells are EPCR positive as described previously
(16), T2 cells are positive for TM alone, and ET1 and ET2
are dual-positive cell lines expressing both EPCR and TM.
Stable antigen expression was demonstrated by flow cy-
tometer analysis as shown in Fig. 4. Protein C was incu-
bated with these cell lines in the presence of thrombin and
the subsequently generated APC was measured. Throm-
Figure 1. Immunoperoxidase
staining of EPCR. Sections of hu-
man aorta (A) and lung (C) were
stained with an anti-EPCR mono-
clonal antibody, JRK-1, by using
biotinylated anti–mouse goat Ig
and avidin-linked peroxidase. In
control experiments, the sections
were stained with the same re-
agents, but without the first anti-
body (B and D). The endothelial
cells in aorta were positive for the
antigen (A), and those in lung cap-
illary were negative (C). 
Figure 2. Surface expression of EPCR and TM on cultured endothelial
cells. In vitro cultured AECs (top) and VECs (bottom) were stained with
JRK-1 (an anti-EPCR monoclonal antibody, left) or CTM1009 (anti-TM
monoclonal antibody, right). The antigens expression was detected by
flow cytometer analysis using FITC-conjugated anti–mouse Ig. The x-axis
represents the fluorescence intensity (log scale) and the y-axis represents
relatively cell number.  
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bin-mediated protein C activation was not detectable on the
negative control N1 cells. EPCR-positive E7 also could
not promote activation. On the other hand, thrombin-
dependent protein C activation was detected with cells
positive for TM. T2 cells promoted activation only in the
presence of thrombin. The activation was completely in-
hibited by a functional blocking anti-TM monoclonal anti-
body, CTM1009 (Fig. 5 
 
A
 
). These results indicated that
activation of protein C on T2 cells was mediated by the
thrombin–TM complex. However, the conversion rate was
quite low when the rate per cell was calculated. In contrast,
dramatic activation was demonstrated with EPCR/TM
dual-positive cells (Fig. 5 
 
A
 
). Five to six times more activa-
tion was detected in the case of dual-positive cells as com-
pared with cells positive for TM alone. 
We next compared APC generation by T2 cells and ET1
cells in the presence of increasing protein C concentration
(Fig. 5 
 
B
 
). Protein C activation by T2 cells was greatly de-
pendent on the protein C concentration. On the other
hand, dual positive ET1 cells could promote significant ac-
tivation, even at the lowest concentration of protein C.
The 
 
K
 
d
 
 value of the reaction was calculated as 869 
 
6
 
 396
nM for T2 cells (Fig. 5 
 
D
 
) and 140 
 
6
 
 43 nM for ET1 cells
Figure 3. Protein C activation
by cultured endothelial cells.
Protein C was incubated with
venous (A and B) or arterial (C
and D) endothelial cells in the
presence of thrombin, and gen-
erated APC was measured. The
y-axis represents velocity of APC
generation (pM/min) in the
presence of indicated concentra-
tions of protein C (A and C).
The Vmax and Kd values were
calculated by the Eadie-Hostee
plot (B and D). 
 
Figure 4.
 
Surface expression EPCR and TM on transfected cell lines.
Cells were stained with CTM1009 (
 
left
 
) or JRK-1 (
 
right
 
) monoclonal an-
tibodies. The antigen expression was analyzed by flow cytometer analysis.
N1 is a negative control cell line. E7 was established from cells transfected
with EPCR. T2 was from TM-transfected cells. ET1 and ET2 were from
dual-transfected cells with both EPCR and TM.  
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(Fig. 5 
 
C
 
). The low-affinity reaction by cells positive for
TM alone and the high-affinity reaction by dual-positive
cells were also demonstrated with the other cell lines (data
not shown). The 
 
K
 
d
 
 value obtained using T2 cells was
identical with that calculated in a reconstitution experi-
ment using solubilized TM in phospholipid membranes
(11). In contrast, the 
 
K
 
d
 
 value for ET1 cells was almost
identical with that of AEC (Fig. 3). Therefore, EPCR/TM
dual-positive cells, but not cells positive for TM alone,
might mimic the protein C activation mechanism observed
in in vitro cultured endothelial cells. TM appears to be an
essential component for activation even in the presence of
EPCR, because complete inhibition of protein C activa-
tion could be demonstrated again using the anti-TM mono-
clonal antibody (Fig. 5 
 
A
 
).
To analyze the function of EPCR on endothelial cells,
we established several functional blocking monoclonal an-
tibodies against EPCR (Ye X., N. Tsuneyoshi, K. Fuku-
dome, and M. Kimoto, unpublished data). One of these,
RCR-252 (rat IgG1), was found to inhibit APC binding to
EPCR-expressing cells (Fig. 6 
 
A
 
). RCR-252 also inhibited
protein C activation mediated not only by EPCR/TM
dual-transfected ET1 cells (Fig. 6 
 
B
 
), but also by primary
cultured AECs (Fig. 6 
 
C
 
) in the same manner. The inhibi-
tory effect of RCR-252 was specific for EPCR function
since protein C activation mediated by TM single-positive
T2 cells was not affected (Fig. 6 
 
B
 
). Therefore, EPCR on
cultured AECs appears to function for protein C activation.
Inhibition of protein C activation by RCR-252 was only
partial (
 
z
 
60%), in sharp contrast with the complete inhibi-
tion by anti-TM antibody (Fig. 6 
 
C
 
). This would be par-
Figure 5. Protein C activation by transfected
cells. Monolayers of indicated cells were incu-
bated with 300 nM of protein C and 0.1 U of
thrombin in the absence or presence of 10 mg/
ml of CTM1009, and then the generated APC
was measured (A). ET1, T2, and N1 cells were
incubated with indicated concentrations of pro-
tein C in the presence of thrombin, and the
generated APC was measured (B). The Kd and
Vmax values of protein C activation by ET1 cells
(C) or T2 cells (D) were calculated by the
Eadie-Hostee plot.
Figure 6. Effects of anti-EPCR monoclonal antibodies on APC bind-
ing and protein C activation. ET1 cells were treated with indicated con-
centrations of a functional blocking anti-EPCR monoclonal antibody,
RCR-252 (closed circles) or a nonblocking RCR-122 (open circles), and
then incubated with 300 nM of APC. After washing, amidolytic activity
of bound APC was measured by using S-2366 and indicated as the maxi-
mum velocity (A). ET1(closed circles), T2 (closed squares), and N1 (closed tri-
angles) cells were treated with indicated concentrations of RCR-252. As a
negative control, RCR-122 was used (open circles). Cells were then incu-
bated with 300 nM of protein C and 0.1 U of thrombin. Generated APC
was measured and indicated as described above (B). After incubation of
AECs with RCR-252 (circles), CTM1009 (squares), or RCR-252 (trian-
gles), APC generation was measured (C). 1034 Activation Mechanism of Protein C Involving EPCR
tially due to the fact that EPCR is a regulatory, but not an
essential, component for the catalytic reaction in such a
way that EPCR amplifies dramatically the reaction medi-
ated by the thrombin–TM complex (Fig. 5). In addition,
binding of APC to ET1 cells by RCR-252 is not blocked
completely. Approximately 10% of binding still remains,
even in the presence of the highest concentration of the
antibody (Fig. 6 A). Therefore, actual contribution of
EPCR on protein C activation would be greater than that
shown in Fig. 6. 
Since the presence of EPCR reduced the Kd value for
protein C activation mediated by the thrombin–TM com-
plex, EPCR appears to concentrate protein C on the en-
dothelial cell surface. Protein C appears to change confor-
mation when it binds to EPCR because the velocity of the
catalytic reaction mediated by the thrombin–TM complex
increased in the presence of EPCR. Although EPCR can
bind protein C with high affinity, the binding has been
demonstrated as a reversible reaction (15). Therefore, bound
protein C should be replaced continuously in circulation.
By these mechanisms, protein C activation appears to be
promoted effectively on the endothelial cell surface. Whether
EPCR and TM exist as a complex on the endothelial cell
surface or the complex is formed after binding of protein C
to EPCR remains to be investigated.
 Clinical studies related to the protein C pathway have
been mainly focused on thrombosis in microvessels, since
until now protein C activation has been considered to be
restricted to the microcirculation (Fig. 7 A). However, in
this study, we have demonstrated a novel mechanism for
APC generation involving EPCR (Fig. 7 B). The high-
affinity protein C receptor is expressed in large vessels in
which protein C activation has been believed unlikely to
occur. EPCR appears to enable significant levels of protein
C activation in large vessels under physiological conditions.
Generation of APC might function as an important regula-
tory mechanism for blood coagulation in large vessels. In
fact, some clinical reports of arterial thrombosis appear to
be related to defects in the protein C pathway (22–24). In
the microvessels, we could not detect EPCR. Whether the
physical condition of increasing the endothelial cell surface
area to blood volume make up the low-affinity reaction or
another unidentified molecule is involved in the activation
remains to be investigated. 
Figure 7. Hypothetical mod-
els for protein C activation on
the endothelial cell surface. In
microvessels, EPCR is not de-
tectable. In the absence of
EPCR, protein C activation me-
diated by the thrombin–TM
complex is a relatively low-affin-
ity reaction. For significant levels
of protein C activation to occur,
an increasing ratio of endothelial
cell surface area to the blood vol-
ume is required (A). In the large
vessels, the high-affinity binding
of protein C to EPCR on the
endothelial cells is a critical step
for activation (B). After binding
to EPCR, the structure of pro-
tein C is modulated to enable
rapid conversion to the active
form.
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